Nurix Therapeutics Q3 2026 Results: Turns Profitable, Net Income $550M
Nurix Therapeutics reported a significant swing to profitability for the quarter ended August 31, 2026, with net income of $549.8 million compared to a net loss of $86.4 million in the prior year, primarily driven by $653.2 million in license revenue. The company's cash position strengthened significantly to $720.2 million, up from $247.0 million at the end of fiscal 2025.
- Key figure
- Net income $550M